Fdps, also known as Farnesyl diphosphate synthase, is an enzyme in the mevalonate pathway. This pathway is crucial for the synthesis of important molecules like cholesterol and isoprenoids. Fdps catalyzes the production of farnesyl diphosphate, which is a key intermediate in multiple downstream biosynthetic processes, thus being of great biological importance in various cellular functions [1].

In prostate cancer, in vitro and in vivo studies using PTEN-conditionally knockout mice showed that FDPS overexpression synergizes with PTEN deficiency. FDPS promotes oncogenic phenotypes such as colony formation and proliferation through activation of AKT and ERK signaling by prenylating Rho A, Rho G, and CDC42 small GTPases. In glioma, FDPS level is enhanced in tissues, contributing to tumour growth. It activates the Wnt/β-catenin signalling pathway and facilitates macrophage infiltration by inducing CCL20 expression [1,2].

In conclusion, Fdps plays a significant role in cancer-related biological processes. Through in vivo studies using gene knockout models like PTEN-conditionally knockout mice, the oncogenic role of Fdps in prostate cancer and glioma has been revealed. These findings provide insights into potential therapeutic targets for these diseases, highlighting the importance of Fdps in understanding cancer development mechanisms.